跳到正文
原文
Medical Xpress·· 2026-10-08AI 评分40

低风险前列腺癌中识别出与更侵袭性癌症相关的分子特征

Low-risk prostate tumors reveal molecular signs linked to more aggressive cancer

AI 导读

KTH皇家理工学院团队在npj Digital Medicine发表研究,结合多组学分析与机器学习,在临床低风险前列腺癌患者亚群中识别出与更侵袭性癌症相关的分子特征,提示常规临床风险分级可能遗漏生物学差异。该方法目前处于研究阶段,尚未用于临床;下一步将通过实验室实验验证分析提示的潜在治疗靶点。

正文
Low-risk prostate tumors reveal molecular signs linked to more aggressive cancer
Dynamic topological rewiring of the ZNF268 network captures an active transitional state. Credit: npj Digital Medicine (2026). DOI: 10.1038/s41746-026-03254-5

A new study revealed molecular features linked to more aggressive prostate cancer in a subset of patients who had been classified as low risk, highlighting biological differences that may not be apparent from clinical measures alone. The results could lead to new therapeutic strategies.

The results were published in npj Digital Medicine by researchers at KTH Royal Institute of Technology, who combined multi-omics analysis of different molecular layers with machine learning, modeling and network analysis. This new approach reveals molecular features of aggressive prostate cancer that are not captured by conventional clinical risk classification.

"The study is a good example of the type of data-driven precision medicine research we are building at KTH, combining large-scale molecular data with machine learning to address clinically relevant questions in cancer," says assistant professor Arian Lundberg, whose A.Lundberg Lab has launched one of the largest national and international efforts to study the tumor microbiome, using extensive Swedish and global clinical cohorts.

The multi-omics approach means that the researchers look at different molecular measurements to tell the complete story of a tumor.

"For example, genomics tells us about DNA alterations, transcriptomics tells us which genes are active, and epigenomics tells us about regulatory changes that can influence gene activity," Lundberg says. "Instead of looking at these layers separately, we integrate them to build a more complete, patient-specific picture of tumor biology."

Machine learning and network analysis were central to the study and its findings. The study's machine-learning model was developed by a team led by assistant professor Golnaz Taheri at the Department of Computational Science and Technology at KTH.

At the moment, the new method is at the research stage and not yet ready for clinical use. The next step is to test some of the potential therapeutic vulnerabilities suggested by the analysis through laboratory experiments. This will help Lundberg's team understand whether the molecular changes they identified are useful for risk prediction alone or may also point toward new therapeutic strategies.

"In the longer term, the goal is to translate these findings into more precise risk stratification and to potentially identify patients who could benefit from earlier or more targeted treatment," Lundberg says.

Publication details

Alexandra Rafeletou et al, A novel multiomics machine learning signature identifies rapid progression in clinically low risk prostate cancer, npj Digital Medicine (2026). DOI: 10.1038/s41746-026-03254-5

Journal information: npj Digital Medicine

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Alexander Pol

Alexander Pol

PhD nano-engineering from Delft University. Published researcher and journal reviewer. Brings scientific insight to content standards. Full profile →

Citation: Low-risk prostate tumors reveal molecular signs linked to more aggressive cancer (2026, October 7) retrieved 7 October 2026 from https://medicalxpress.com/news/2026-10-prostate-tumors-reveal-molecular-linked.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com